Escherichia coli is a Gram-negative bacteria that causes various diseases, including pneumonia, urinary tract infections, and diarrhoea. The present work is an effort to study antimicrobial resistance pattern in this bacteria. Clinical samples (6840) were collected from King Fahd Hospital in Madinah, Saudi Arabia and screened for E. coli strains. Of all positive samples obtained from different clinical sources, about 3% isolates represented E. coli and 71.6% of these were collected from clinical samples of male patients. E. coli isolates were recovered from sputum (20.58%), wound (55.88%), and catheters tips (9.31%) representing about 86% of all clinical specimens. Antimicrobial susceptibility pattern of the E. coli isolates to twelve different antimicrobials revealed that all the isolates (100%) were susceptible to imipenem, amikacin, and aztreonam. Cefoxitin, ceftazidime and ciprofloxacin showed a sensitivity of 98.7%. This was followed by gentamycin (98.6%), piperacillin (95.7%), cotrimoxazole (92.3%), cephalothin (91.4%), and Augmentin (91.1%). Ampicillin showed the least susceptibility of 87.5%. Hence, cotrimoxazole, Augmentin, and ampicillin should be prescribed with care in order to avoid increasing resistance patterns in E. coli. Results also demonstrate that frequency of E. coli infections was highest during summer and winter seasons representing about 30% each. Autumn season, which coincided with the season of pilgrimage, recorded about 22% of infections while spring season had the least recorded percentage with only 17% of infections. This study is therefore a step towards the generation of national data on the prevalence of antimicrobial resistance patterns of E. coli.
Pseudomonas spp. are the leading cause of nosocomial infections. Rise in multidrug resistance among clinical isolates limit therapeutic options and hence increase mortality rate. Clinical samples (6840) from a hospital in Madinah, Saudi Arabia were collected for a duration of 14 months to study the frequency, antimicrobial sensitivity pattern and seasonal variations of Pseudomonas isolates. Conventional biochemical tests were done to identify the probable organism and antibiotic susceptibility was performed by disc diffusion method and Phoenix automated microbiology 100 ID/AST system. Pseudomonas represented 6.5% of all positive samples of which 65% were from males. Majority of the organisms (85%) were isolated from sputum and wound swabs followed by catheter tips (6.4%) and throat aspirates (3.4%). From the remaining samples, less than 1% organisms were obtained. Assessment of antimicrobial susceptibility to 11 different antibiotics revealed that imipenem was the most effective with highest sensitivity of 99.5%, and low intermediate resistance of only 0.5%. This was followed by ciprofloxacin (97.5%), ceftazidime (96.3%), cefpiramide/amikacin (94.1%), aztreonam (93.2%), gentamycin (87.7%), ampicillin (83%), and cotrimoxazole (80.1%). The most resistant drugs included augmentin (25%), cotrimoxazole (19.9%), ampicillin (17%) and gentamycin (12.3%) while the least resistant were ciprofloxacin (1.5%) and imipenem (0%). Results recommend imipenem as a promising antibiotic against Pseudomonas infections. In case of resistance to imipenem, ciprofloxacin, ceftazidime, cefpiramide, amikacin, and aztreonam may be recommended. In acute cases, Pseudomonas infections may require combined antimicrobial therapy. Frequency of these infections was the lowest (17%) during spring. It was the highest (30%) during summers and winters but reduced to 22% during autumn maybe due to better hygiene during pilgrimage season.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.